The MEK1/2 inhibitor binimetinib potentiated the activity of venetoclax and ABT-737 under conditions that mimic the CLL tumor microenvironment via downregulation of MCL-1 activity, BIM and BCL-xL expression109. The gene discussed is MCL1; the disease is B-cell chronic lymphocytic leukemia.